Summit Therapeutics Plc (SUMM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013619
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the infectious disease caused by the bacteria C difficile. It develops ridinilazole, an antibiotic that has the potential to treat CDI and reduce disease recurrence. Summit undertakes utrophin modulation program for duchenne muscular dystrophy. The company also develops novel antibiotic program for the treatment of superbug C. difficile. It operates through other pharmaceutical companies and charity foundations and parent advocacy groups. The company operates through its office located in Cambridge, the US. Summit is headquartered in Abingdon, the UK.

Summit Therapeutics Plc (SUMM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Summit Therapeutics Plc, Medical Devices Deals, 2011 to YTD 2017 10
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 12
Summit Therapeutics Enters into Agreement with University of Oxford 13
Licensing Agreements 14
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 14
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 15
Equity Offering 16
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 16
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 18
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 19
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 20
Summit Completes Private Placement Of Shares For US$34.4 Million 22
Summit Completes Private Placement Of Shares For US$1.6 Million 23
Summit Completes Private Placement Of Shares For US$7 Million 24
Summit Completes Private Placement Of Shares For US$0.1 Million 25
Summit Announces Private Placement Of Shares For US$8 Million 26
Summit Completes Private Placement Of Common Stock For US$2.2 Million 27
Acquisition 28
Summit Acquires MuOx for USD5.3 Million 28
Summit Therapeutics Plc – Key Competitors 29
Summit Therapeutics Plc – Key Employees 30
Summit Therapeutics Plc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 31, 2017: Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress 32
Jun 14, 2017: Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2017 And Operational Progress 35
Mar 29, 2017: Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress 37
Dec 15, 2016: Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress 38
Sep 08, 2016: Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2016 And Operational Progress 39
Jun 02, 2016: Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress 40
May 10, 2016: Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016 41
Corporate Communications 42
May 23, 2017: Summit Announces Key Appointments to Strengthen Research & Development Team 42
Jan 18, 2017: Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development 44
Product News 45
03/15/2016: Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD 45
Clinical Trials 46
Jan 21, 2016: Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD 46
Other Significant Developments 47
Mar 30, 2017: Summit Therapeutics: Change of Registered Office 47
Mar 30, 2017: Summit Announces Change Of Registered Company Address 48
Sep 12, 2016: Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Summit Therapeutics Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Summit Therapeutics Plc, Medical Devices Deals, 2011 to YTD 2017 10
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 12
Summit Therapeutics Enters into Agreement with University of Oxford 13
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 14
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 15
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 16
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 18
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 19
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 20
Summit Completes Private Placement Of Shares For US$34.4 Million 22
Summit Completes Private Placement Of Shares For US$1.6 Million 23
Summit Completes Private Placement Of Shares For US$7 Million 24
Summit Completes Private Placement Of Shares For US$0.1 Million 25
Summit Announces Private Placement Of Shares For US$8 Million 26
Summit Completes Private Placement Of Common Stock For US$2.2 Million 27
Summit Acquires MuOx for USD5.3 Million 28
Summit Therapeutics Plc, Key Competitors 29
Summit Therapeutics Plc, Key Employees 30
Summit Therapeutics Plc, Subsidiaries 31

★海外企業調査レポート[Summit Therapeutics Plc (SUMM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • VidaCaixa, S.A.U. de Seguros y Reaseguros:企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Turkiye Garanti Bankasi AS:戦略・SWOT・企業財務分析
    Turkiye Garanti Bankasi AS - Strategy, SWOT and Corporate Finance Report Summary Turkiye Garanti Bankasi AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Hagoromo Foods Corp:企業の戦略・SWOT・財務分析
    Hagoromo Foods Corp - Strategy, SWOT and Corporate Finance Report Summary Hagoromo Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Proximus SA (formerly Belgacom SA):企業のM&A・事業提携・投資動向
    Proximus SA (formerly Belgacom SA) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Proximus SA (formerly Belgacom SA) Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • TIBCO Software, Inc.:企業のM&A・事業提携・投資動向
    TIBCO Software, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's TIBCO Software, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Micron Technology Inc:企業の戦略・SWOT・財務情報
    Micron Technology Inc - Strategy, SWOT and Corporate Finance Report Summary Micron Technology Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Abu Dhabi Commercial Bank P.J.S.C.:戦略・SWOT・企業財務分析
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • National Oilwell Varco Inc (NOV):企業の財務・戦略的SWOT分析
    National Oilwell Varco Inc (NOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Modern Times Group MTG AB:企業の戦略・SWOT・財務情報
    Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report Summary Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Daimler AG (DAI)-エネルギー分野:企業M&A・提携分析
    Summary Daimler AG (Daimler) is an automobile company that undertakes the manufacture, distribution and sales of premium passenger cars, commercial vehicles and related spare part and accessories. The company also provides services such as financing, leasing, fleet management, insurance, financial i …
  • Vectren Corp (VVC):石油・ガス:M&Aディール及び事業提携情報
    Summary Vectren Corp (Vectren) is an energy holding company, which carries out the distribution and transmission of natural gas and electricity. Under its wholly owned subsidiary, Vectren Utility Holdings, Inc., the company operates three utilities; Vectren Energy Delivery of Indiana - North (Vectre …
  • Neue Bank AG:企業の戦略・SWOT・財務情報
    Neue Bank AG - Strategy, SWOT and Corporate Finance Report Summary Neue Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Country Club Hospitality & Holidays Ltd.
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • NuStar Energy LP (NS):石油・ガス:M&Aディール及び事業提携情報
    Summary NuStar Energy LP (NuStar Energy) is a midstream oil and gas company. It carries out the transportation, terminalling, storage and marketing of petroleum products, and anhydrous ammonia. The company owns and operates pipelines, terminal and storage facilities that store and distribute crude o …
  • Evgen Pharma Plc (EVG)-製薬・医療分野:企業M&A・提携分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a drug discovery company that develops medicines to treat cancer and neurological diseases. The company uses sulforadex technology that synthesizes and concurrently stabilizes the naturally occurring compound such as sulforaphane. …
  • Environmental Container Systems, Inc.:企業の戦略・SWOT・財務情報
    Environmental Container Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Environmental Container Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • FuelCell Energy Inc (FCEL):企業の財務・戦略的SWOT分析
    FuelCell Energy Inc (FCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Allergan plc:企業のM&A・事業提携・投資動向
    Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Siemens Healthcare GmbH (SHL):医療機器:M&Aディール及び事業提携情報
    Summary Siemens Healthcare GmbH (Siemens Healthineers), a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT, laboratory diagnostics equipm …
  • Pharmathen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Pharmathen Pharmaceuticals SA (Pharmathen) is a healthcare products provider that develops and markets generic products. The company’s products include oral antiplatelet agent, bactericidal cephalosporin antibiotic, retinoid, beta1-selective adrenergic receptor blocking agent, and others. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆